Technical Analysis for ARVN - Arvinas, Inc.

Grade Last Price % Change Price Change
grade A 34.71 1.89% 0.65
ARVN closed up 1.89 percent on Thursday, November 21, 2019, on 65 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The bulls were able to push the stock to a new 52-week high. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Up Up Up
See historical ARVN trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
NR7 Range Contraction 0.00%
New 52 Week High Strength 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
New 52 Week Closing High Bullish 1.89%

Older signals for ARVN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Analyze My Stocks!
Configure default chart indicators
ARVN Chart by TradingView
Basic chart:
Profile
Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Arvinas uses its proprietary technology platform to engineer proteolysis targeting chimeras, or PROTAC™ protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.
Biopharmaceutical Biology Diseases Genetics Metabolism
Is ARVN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Nov 21 Arvinas Appoints Laurie Smaldone Alsup, M.D., to Board of Directors
Nov 20 The Daily Biotech Pulse: Endo's Cellulite Treatment Accepted For Review, Diffusion Pharma Reports Positive Glioblastoma Data
Nov 17 Notable Insider Buys In The Past Week: Arvinas, Dropbox, Trinity
Nov 14 JPMorgan likes Qiagen in premarket analyst action
Nov 7 Arvinas, Inc. Announces Pricing of Public Offering of Common Stock
Nov 6 Arvinas, Inc. Announces Proposed Offering of Common Stock
Nov 5 Arvinas, Inc. (ARVN) Upgraded to Strong Buy: Here's Why
Nov 4 Arvinas EPS misses by $0.07, beats on revenue
Nov 4 Arvinas Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Oct 31 Goldman Sachs: 3 Standout Healthcare Stocks That Could Double
See more ARVN news...
Indicators
Indicator Value
52 Week High 34.94
52 Week Low 10.19
Average Volume 348,617
200-Day Moving Average 21.8801
50-Day Moving Average 22.476
20-Day Moving Average 25.8193
10-Day Moving Average 29.9275
Average True Range 1.7384
ADX 54.28
+DI 44.0952
-DI 4.2528
Chandelier Exit (Long, 3 ATRs ) 29.7248
Chandelier Exit (Short, 3 ATRs ) 22.2152
Upper Bollinger Band 35.3812
Lower Bollinger Band 16.2574
Percent B (%b) 0.96
BandWidth 74.067848
MACD Line 3.4989
MACD Signal Line 2.4303
MACD Histogram 1.0686
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 36.35
Resistance 3 (R3) 36.24 35.59 36.07
Resistance 2 (R2) 35.59 35.17 35.64 35.98
Resistance 1 (R1) 35.15 34.92 35.37 35.26 35.89
Pivot Point 34.50 34.50 34.61 34.55 34.50
Support 1 (S1) 34.06 34.08 34.28 34.17 33.53
Support 2 (S2) 33.41 33.83 33.46 33.44
Support 3 (S3) 32.97 33.41 33.35
Support 4 (S4) 33.08